SARcode Bioscience Inc. announced the topline results from OPUS-1, a pivotal phase III study of lifitegrast ophthalmic solution 5.0% for the treatment of dry eye disease.
Blinding eye disease linked with forms of cardiovascular disease
Boarding Orbis Flying Eye Hospital: Not your typical flight experience
EP. 5: EyeCon 2022: Last chance to earn those end-of-year CME credits
